---
title: Wellness First, Medical Device Later: The Two-Stage Launch Strategy
description: Some MedTech products can launch as wellness first and later transition to medical device status. Here is when the strategy works, when it does not, and the legal boundary.
authors: Tibor Zechmeister, Felix Lenhard
category: MedTech Startup Strategy & PMF
primary_keyword: wellness first medical device later
canonical_url: https://zechmeister-solutions.com/en/blog/wellness-first-medical-device-later
source: zechmeister-solutions.com
license: All rights reserved. Content may be cited with attribution and a link to the canonical URL.
---

# Wellness First, Medical Device Later: The Two-Stage Launch Strategy

*By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.*

> **Launching a product as a wellness offering first and transitioning to a medical device after product-market fit is a legitimate strategy when the wellness version genuinely does not meet the MDR Article 2(1) medical device definition. The boundary is set by the manufacturer's stated intended purpose under Article 2(12). Change the words on the label, the IFU, the marketing, and the clinical evaluation, and you change what the regulation sees. Keep making medical claims while calling the product wellness, and you have an unlicensed medical device on the market.**

**By Tibor Zechmeister and Felix Lenhard. Last updated 10 April 2026.**

---

## TL;DR

- The wellness-first strategy launches a product with a non-medical intended purpose, validates demand, and transitions to medical device status under MDR only after product-market fit is proven.
- The legal boundary is set by MDR Article 2(12), which defines intended purpose as the manufacturer's own written statements on the label, in the IFU, in promotional and sales materials, and in the clinical evaluation.
- The strategy is legitimate when the wellness version does not make diagnostic, therapeutic, preventive, or monitoring claims that would trigger the Article 2(1) medical device definition.
- The strategy is not legitimate when the product still makes medical claims under a "wellness" label. That is not positioning. That is a non-compliant medical device.
- A real Graz case: a small, deliberate revision to the intended purpose — not to the technology or the product — moved a product cleanly into wellness territory and accelerated market entry by years.
- What you say on your website, in investor pitches, and in sales calls is regulated speech under Article 2(12) and Article 7, not marketing freedom.
- The disciplined version of this strategy ships sooner and keeps optionality. The sloppy version ships a liability.
- When PMF is proven and medical claims become strategically necessary, the transition to CE-marked medical device follows the same MDR path any other manufacturer would follow. There is no shortcut at the transition.

---

## A Graz company that found product-market fit in wellness first

A company in Graz came to us with what they believed was a medical device project. The product existed. The technology worked. The founders had written an intended purpose statement that described therapeutic benefits and included language about supporting patients with a specific condition. On that statement, the product was a medical device under Article 2(1), and the MDR clock had started the moment they thought about selling it.

We looked at what they were actually building and what they actually wanted to claim at the point of launch. The honest answer was: not much that required the medical device definition. The product helped users feel better, track something, do something they wanted to do. The medical framing had crept in because the founders came from a medical background and because "medical device" sounded more serious than "wellness product."

So we rewrote the intended purpose. Not the product. Not the technology. Not the data flow, not the user experience, not the business model. Just the words — on the label, in the draft IFU, on the website, in the investor deck, in the founders' talking points for sales conversations. The product was reclassified as a wellness offering because, under the new words, it honestly did not meet the Article 2(1) medical device definition anymore.

The company entered the market months ahead of any MDR path. They sold the product. They learned what their customers actually wanted. The option to add medical claims later and go through CE marking when the business case justified it stayed on the table. That is the wellness-first, medical-device-later strategy in one sentence.

## The strategy explained

Wellness-first is a two-stage launch pattern. Stage one: ship the product under an intended purpose that does not make it a medical device. Sell it, learn, iterate on the business model, build evidence about what users actually value. Stage two: if and when the strategic case for medical claims is strong enough, add those claims deliberately and walk the full MDR path — technical documentation, risk management, clinical evaluation, QMS, notified body assessment where required, CE marking.

The stages are sequenced for one reason: the first stage validates market demand with a fraction of the time, capital, and regulatory exposure of the second. You learn whether anyone wants this before you spend two years and several hundred thousand euros certifying it.

This is not a regulatory loophole. It is the honest application of the fact that the MDR regulates based on the manufacturer's stated intended purpose, not on what the technology could theoretically do. If your intended purpose is not medical, your product is not a medical device, and MDR does not apply. The moment your intended purpose becomes medical, it does.

## The legal line drawn by intended purpose — Article 2(12) verbatim

The MDR defines intended purpose explicitly. This is the single sentence the entire strategy hinges on:

> *"'intended purpose' means the use for which a device is intended according to the data supplied by the manufacturer on the label, in the instructions for use, or in promotional or sales materials or statements, and as specified by the manufacturer in the clinical evaluation."* — Regulation (EU) 2017/745, Article 2, point (12).

Four sources. The label. The instructions for use. Promotional or sales materials or statements. The clinical evaluation. The regulator reads all four and builds a single picture of what you, the manufacturer, say the product is for. Then Article 2(1) tests that picture against the medical device definition. If the picture includes diagnosis, prevention, monitoring, prediction, prognosis, treatment, or alleviation of disease, injury, or disability for the benefit of individual patients, the product is a medical device. If the picture does not include any of that, it is not.

This means the wellness-first strategy succeeds or fails on a four-source audit. Every surface where your company speaks about the product is evidence. A website paragraph contradicts a careful IFU? The website is part of the intended purpose. A sales deck slide promises a therapeutic outcome the label never mentions? The slide is part of the intended purpose. A founder interview with a startup magazine claims the product treats something? That statement is part of the intended purpose under the "promotional or sales materials or statements" clause.

Article 7 reinforces this by prohibiting misleading claims and prohibiting the attribution of functions and properties the device does not have. You cannot call something wellness in the footer and claim it diagnoses something in the headline. Article 7 closes that door from the other side.

## When the strategy is legitimate

The wellness-first path is legitimate when every one of the following holds:

- The product as described in all four Article 2(12) sources genuinely does not meet the Article 2(1) medical device definition. No diagnostic language. No therapeutic promises. No prevention of disease claims. No monitoring of a medical condition as an explicit purpose.
- The company accepts the commercial consequences of a non-medical positioning — typically less clinical credibility, different buyer psychology, and no reimbursement pathway until medical device status is earned.
- The team maintains discipline across every surface. Marketing cannot be allowed to drift into medical claims because a competitor did or because a press interview went off-script. Every speaker who touches the product needs to know what is on-message and what is off-message.
- The transition plan to medical device status is explicit from day one, even if the execution date is open. Going wellness-first without a considered view of when and how the MDR path would be entered is not strategy. It is procrastination.
- The product itself is honest about what it does. A product that clearly improves a wellness-relevant outcome (sleep quality, general fitness, comfort, relaxation, tracking of non-medical metrics) has room to live in wellness. A product whose entire reason to exist is to change a clinical outcome does not.

The Graz case met all of these conditions. The product was genuinely useful under a non-medical framing. The founders were willing to let go of the medical positioning at launch. The word changes were consistent across every surface. And the transition path was understood — if the business case for medical claims became compelling, the MDR route was available.

## When the strategy is not legitimate

The failure mode is worse than never trying the strategy at all. A product sold with medical claims under a wellness label is an unregistered medical device on the market. That is an Article 5 violation, an Article 7 violation, and, depending on the member state, a matter for the competent authority under national enforcement regimes.

The strategy is not legitimate when:

- The website, sales copy, or investor deck makes claims that meet the Article 2(1) definition while the label or IFU says "wellness." The four sources in Article 2(12) are not a menu. They all count simultaneously.
- The product is physically identical to a medical device competitor and is positioned "for the same users and the same outcomes" in sales conversations, even if the formal intended purpose statement is carefully written. Sales statements are explicitly named in Article 2(12).
- The founders plan to "prove the product works clinically" as part of the wellness phase — generating clinical evidence that the wellness product treats a condition is the act of describing a medical device.
- The product category has established regulatory precedent that makes the medical framing mandatory. The Borderline Manual v4 records many cases where the BCWG has concluded that a given technology and claim pattern cannot be anything other than a medical device. Trying to run wellness-first against settled precedent is not a strategy.
- The company intends to "test the market" by making medical claims quietly and pulling them back if regulators notice. That is not a launch strategy. That is a probability-weighted plan to break the law.

The shorthand: if rewriting the intended purpose to a non-medical framing requires the product to be honestly something other than a medical device, the strategy can work. If it requires the marketing team to lie, it cannot.

## What you can say in wellness positioning

Wellness positioning is not silent positioning. There is real language available that is commercially useful and stays on the non-medical side of Article 2(1):

- Improvements in general well-being, comfort, relaxation, energy, or mood that are not framed as treatment of a diagnosed condition.
- Tracking of metrics the user finds interesting, explicitly outside a clinical context (steps, sleep patterns, general activity, self-reported states).
- Support for lifestyle goals the user sets for themselves — fitness, mindfulness, habit building, personal curiosity about their body.
- Features that inform without diagnosing — showing the user data, letting them decide what to do with it, not interpreting the data against medical thresholds.
- Safety and quality claims about the product itself (materials, build quality, data handling) that do not imply a clinical effect on the user.

The test on every sentence: does this sentence, if a regulator read it, describe a medical purpose under Article 2(1)? If the answer is no, the sentence lives in wellness. If the answer is yes or even "maybe," the sentence is a medical claim and belongs on the other side of the transition.

## What you cannot say — the claims trap

This is where wellness-first launches die. A company goes to market with a careful IFU and then, somewhere, somebody writes one sentence that tips the whole product into the medical device definition.

Examples from real files we have reviewed:

- "Clinically proven to reduce anxiety." That is a therapeutic claim. The word "clinically" raises the stakes; the word "reduce" with a named condition crosses the Article 2(1) line.
- "Helps manage your blood pressure." "Manage" plus a clinical parameter is monitoring and, by implication, treatment support. Medical device.
- "Detects early signs of X." "Detects" plus a condition is diagnosis. Medical device.
- "Recommended by doctors for patients with..." The word "patients" imports the clinical frame. Medical device.
- "The only wellness device approved for use in cardiac rehabilitation." The framing contradicts itself. If it is used in cardiac rehabilitation, it is not wellness.
- "Heals sore muscles after exercise." "Heals" is a therapeutic verb. Medical device.
- Scientific literature on the company website that describes the product as treating a condition, even if the IFU does not. The blog post is "promotional or sales materials" under Article 2(12).
- Investor deck slides that promise a therapeutic market opportunity. Investor materials are promotional materials. What you say to investors is part of the intended purpose in the eyes of a competent authority.

The claims trap is that the cost of writing one of these sentences is zero in the moment and catastrophic later. The moment one of them exists in writing on a company surface, the product is a medical device under Article 2(12), and the wellness-first strategy has quietly failed without anyone noticing.

## The transition from wellness to medical device when PMF is proven

Wellness-first only makes sense if stage two is real. At some point, the business case for medical claims becomes compelling: a payer conversation opens up, a hospital channel requires clinical evidence, a competitor makes CE-marked claims the market starts to expect, reimbursement becomes plausible. That is the moment to transition.

The transition is not a marketing exercise. It is a regulatory project. The company now has to do what every other MDR manufacturer does: define the medical intended purpose, build the technical documentation, apply risk management, generate or compile clinical evidence appropriate to the classification, establish a QMS under EN ISO 13485, engage a notified body where the classification requires it, and earn the CE mark. The wellness phase does not shorten this work. It does, however, fund it — by the time a company has proven PMF in wellness, they are typically in a stronger position to finance the CE path than they would have been at day zero.

The handover matters. On transition day, every Article 2(12) source has to flip coherently. The label, the IFU, the website, the sales materials, the investor communications, and the clinical evaluation all have to tell the new medical story at the same time. Running both stories in parallel — wellness on one page, medical device claims on another — is the worst of both worlds. Either you are a wellness product or you are a CE-marked medical device. Half of each is not legal in either regime.

## The disciplined version vs. the "slap on wellness label" version

Two teams can adopt the same strategy and get opposite results. The difference is discipline.

The disciplined version: the team rewrites the intended purpose deliberately, audits every surface where the product is described, trains every person who might speak about the product on what is on-message, keeps a written file documenting why the wellness positioning is honest, and revisits the positioning every quarter as marketing evolves. The product ships with a consistent story across the four Article 2(12) sources. When PMF is proven, the team consciously decides whether to transition, and when they do, every surface flips together.

The slap-on-wellness-label version: the team adds "wellness" to the packaging, does not change the marketing site, does not retrain sales, does not audit investor materials, lets the medical claims drift back because they convert better, and hopes that nobody looks too closely. The product exists in a regulatory superposition — wellness on the box, medical device in the pitch — until a competent authority or a competitor resolves the superposition by filing a complaint.

The first version is a strategy. The second is a slow-motion compliance failure with a deceptive vocabulary.

## The Subtract to Ship angle

Wellness-first is a textbook subtraction. The question is not "how do we get to a CE mark faster?" The question is "what is the smallest, honest description of this product that still makes it worth selling?" If that description is not a medical device, launching under it is faster, cheaper, and more informative than pushing a medical device through certification on a founder's hunch about what the market will pay for.

The discipline is not in the subtraction itself — any founder can write a simpler intended purpose. The discipline is in keeping every surface consistent with it. A wellness-first launch only saves time if the four Article 2(12) sources agree. The moment one of them drifts, the saved time is eaten by the compliance problem that drift creates.

And the trace to MDR is explicit. This is not an external framework borrowed from lean startup theory. It is the direct consequence of how Article 2(12) and Article 2(1) interact: the regulation keys off the manufacturer's words, so the founder's leverage is at the word level. That leverage is either wasted or used.

## Reality Check — Where do you stand?

1. If you read your current intended purpose statement out loud, is it a medical device under Article 2(1) — and is that what you actually need at launch?
2. Have you audited your website, IFU, promotional materials, and clinical evaluation (or the plan for one) for consistency? Do all four tell the same story?
3. Is there any sentence on your website, in your investor deck, or in your sales scripts that uses a verb from Article 2(1) — diagnosis, prevention, monitoring, prediction, prognosis, treatment, alleviation — that your IFU does not back up?
4. If you went to market tomorrow with the wellness positioning, would you be willing to walk every employee and investor through the language discipline required to keep it honest?
5. Do you have a written transition plan that explains what event would trigger the move to medical device status, and what the MDR path would look like when that event happens?
6. If a competent authority asked you today to defend your non-device position with evidence from all four Article 2(12) sources, could you produce a clean file?
7. Is the wellness positioning genuine, or is it a relabel of a product you already think of as a medical device in everything but the paperwork?

If you cannot answer "yes" to all seven, the strategy is not yet safe to execute.

## Frequently Asked Questions

**Can I legally launch my MedTech product as a wellness product first and become a medical device later?**
Yes, if the wellness version honestly does not meet the MDR Article 2(1) medical device definition based on the manufacturer's stated intended purpose. Article 2(12) sources that statement from the label, the instructions for use, promotional or sales materials or statements, and the manufacturer's specification in the clinical evaluation. The strategy fails the moment any of these starts making a claim that meets the medical device definition.

**What is the exact MDR definition of intended purpose?**
Article 2, point (12) of Regulation (EU) 2017/745 defines it as "the use for which a device is intended according to the data supplied by the manufacturer on the label, in the instructions for use, or in promotional or sales materials or statements, and as specified by the manufacturer in the clinical evaluation." These four sources are read together.

**Can my website say something different from my IFU?**
No. Article 2(12) treats promotional materials and the IFU as part of the same intended purpose. If your website makes medical claims and your IFU does not, the website claims count. The product is classified on the combined picture, and the contradiction is itself an Article 7 problem.

**Does this strategy work for software?**
It can, if the software honestly provides a non-medical function — general wellness tracking, lifestyle information, user-set goal support — and the description across all Article 2(12) sources does not describe diagnosis, monitoring, prediction, or therapeutic decision support. Software that interprets data against clinical thresholds is typically medical device software regardless of wellness framing.

**What happens if a regulator decides I crossed the line?**
The product is treated as an unregistered medical device. Depending on the member state, enforcement can include removal from market, fines, and corrective action requirements. It can also damage the company's position for any future CE marking, because the compliance history is on record.

**When should I actually transition from wellness to medical device status?**
When the business case for medical claims becomes strong enough to justify the full MDR path. Common triggers are a serious payer or reimbursement opportunity, a hospital channel that requires clinical evidence, or a competitive landscape that makes non-medical positioning strategically untenable. The transition is a proper regulatory project, not a marketing decision.

**Is wellness-first the same as the beachhead strategy?**
They are related but not identical. The beachhead strategy is about picking the narrowest, most winnable customer segment to enter first. Wellness-first is about narrowing the intended purpose so the product is not yet a medical device. A startup can combine them, and often should, but each answers a different question — the beachhead answers "who do we sell to first," and wellness-first answers "what are we legally selling."

## Related reading

- [MDR Scope: What the Regulation Covers and What It Does Not](/blog/mdr-scope) — what falls inside the MDR and what stays outside.
- [Medical Device vs. Wellness Product: Where the Line Actually Runs](/blog/medical-device-vs-wellness-product) — the definitional boundary under Article 2(1) and 2(12).
- [Borderline Products Under MDR: How to Determine If Your Innovation Is a Medical Device](/blog/borderline-products-mdr) — how the BCWG resolves the grey zone in practice.
- [The Beachhead Strategy for MedTech Startups](/blog/beachhead-strategy) — focus discipline for early market entry.
- [Minimum Viable Regulatory Strategy: CE Marking With Limited Resources](/blog/minimum-viable-regulatory-strategy-ce-mark-limited-resources) — how to sequence the regulatory path when money is tight.
- [The Subtract to Ship Framework for MDR](/blog/subtract-to-ship-framework-mdr) — the underlying methodology this post applies.
- [Intended Purpose vs. Intended Use Under MDR Article 2(12)](/blog/intended-purpose-vs-intended-use-mdr) — the definitional depth behind this strategy.
- [Claims Management Under MDR](/blog/claims-management-mdr) — how to keep every surface consistent with your intended purpose.
- [Misleading Claims Under MDR Article 7](/blog/misleading-claims-mdr) — what you cannot say, under what law, and why.
- [Product-Market Fit for MedTech Startups](/blog/product-market-fit-medtech-startups) — the PMF question wellness-first is designed to answer cheaply.

## Sources

1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, Article 2(1) (definition of medical device), Article 2(12) (definition of intended purpose), Article 7 (claims). Official Journal L 117, 5.5.2017.
2. Manual on Borderline and Classification for Medical Devices under Regulation (EU) 2017/745 on medical devices and Regulation (EU) 2017/746 on in vitro diagnostic medical devices, Version 4, September 2025.

---

*This post is part of the MedTech Startup Strategy & PMF series in the Subtract to Ship: MDR blog. Authored by Felix Lenhard and Tibor Zechmeister. When the wellness-first strategy is being considered, the cost of an hour spent auditing the four Article 2(12) sources with someone who has defended the position in front of a competent authority is usually the cheapest hour in the launch plan.*

---

*This post is part of the [MedTech Startup Strategy & PMF](https://zechmeister-solutions.com/en/blog/category/startup-strategy) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*